All Stories

  1. Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial
  2. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease
  3. Late Breaking Abstract - A PET imaging study to confirm target engagement in the lungs of patients with IPF following a single dose of a novel inhaled avß6 integrin inhibitor
  4. Home spirometry for idiopathic pulmonary fibrosis: ready for prime time?
  5. Recent advances in understanding idiopathic pulmonary fibrosis
  6. Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?
  7. Current and Future Therapies for Idiopathic Pulmonary Fibrosis
  8. Pirfenidone Post-Authorization Safety Registry (PASSPORT): Update and Concomitant Use of NAC and/or Corticosteroids
  9. Response of the King's brief interstitial lung disease (KBILD) questionnaire to pulmonary rehabilitation (PR)
  10. A comparison of two scoring methods for the King's sarcoidosis questionnaire
  11. Optimal use of gas transfer values in detecting pulmonary vascular involvement in sarcoidosis
  12. Personalized medicine in idiopathic pulmonary fibrosis
  13. New guideline on treatment of idiopathic pulmonary fibrosis
  14. Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease
  15. Transcriptional phenotyping of fibrotic lung disease: a new gold standard?
  16. Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung disease
  17. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
  18. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
  19. Combination therapy: the future of management for idiopathic pulmonary fibrosis?
  20. UK trainee experience in interstitial lung disease: results from a British Thoracic Society survey
  21. Detecting anxiety and depression in patients diagnosed with an interstitial lung disease. Can we do better?
  22. Respiratory microbiome in IPF: cause, effect, or biomarker?
  23. Immunosuppression for Connective Tissue Disease–Related Pulmonary Disease
  24. Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
  25. The treatment of idiopathic pulmonary fibrosis
  26. Year in review 2013: Acute lung injury, interstitial lung diseases, sleep and physiology
  27. Current and Emerging Treatment Options in Interstitial Lung Disease
  28. Idiopathic pulmonary fibrosis
  29. Rituximab in severe, treatment-refractory interstitial lung disease
  30. Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine
  31. The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease
  32. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
  33. Year in review 2012: Acute lung injury, interstitial lung diseases, sleep and physiology
  34. Exercise-induced haemoptysis: a thoroughbred cause?
  35. Successful treatment of progressive diffuse PEComatosis
  36. The Diagnosing and Staging of Idiopathic Pulmonary Fibrosis
  37. A Clinical Approach to Diffuse Parenchymal Lung Disease
  38. Current and novel drug therapies for idiopathic pulmonary fibrosis
  39. Drug-/radiation-induced interstitial lung disease in the United Kingdom general population: Incidence, all-cause mortality and characteristics at diagnosis
  40. Diffuse parenchymal lung disease
  41. A Mucin 5B (MUC5B) Promoter Polymorphism In Sarcoidosis
  42. The Respiratory Microbiome In Idiopathic Pulmonary Fibrosis
  43. Pulmonary Sarcoidosis: Integration Of The Composite Physiologocal Index And HRCT Patterns For Clinical Staging
  44. Year in review 2011: Acute lung injury, interstitial lung diseases, physiology, sleep and lung cancer
  45. Idiopathic Pulmonary Fibrosis: Pathobiology of Novel Approaches to Treatment
  46. Pulmonary fibrosis
  47. Incidence of the Pneumoconioses in the United Kingdom General Population between 1997 and 2008
  48. Rituximab Therapy In Severe Interstitial Lung Disease
  49. Idiopathic pulmonary fibrosis-related pulmonary hypertension; an exercising diagnosis?
  50. Year in review 2010: Interstitial lung diseases, acute lung injury, sleep, physiology, imaging, bronchoscopic intervention and lung cancer
  51. Vibration Response Imaging Correlates With Air Flow Measured By Spirometry
  52. Year in review 2009: Interstitial lung diseases, acute injury, sleep, physiology, imaging and bronchoscopic intervention
  53. Lysophosphatidic Acid Induces αvβ6 Integrin-Mediated TGF-β Activation via the LPA2 Receptor and the Small G Protein Gαq
  54. Understanding Nonspecific Interstitial Pneumonia: The Need for a Diagnostic Gold Standard
  55. The diagnosis of idiopathic pulmonary fibrosis and its complications
  56. Vibration Response Imaging Technology in Healthy Subjects
  57. Native Valve Aspergillus Endocarditis Complicating Lung Transplantation
  58. Diffuse parenchymal lung disease
  59. CT Findings of Varicella Pneumonia After Lung Transplantation
  60. Acute breathlessness
  61. REPRODUCIBILITY OF RELATIVE REGIONAL ASSESSMENT USING THE VIBRATION RESPONSE IMAGING DEVICE
  62. Perspectives for the future